Perspective Therapeutics, Inc. (CATX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US46489V3024
Perspective Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -113.56 m USD |
| EBIT | -112.03 m USD |
| Net income | -103.12 m USD |
| Diluted EPS – continuing operations | -1.40 USD |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
More stocks
- T3 Entertainment Inc. (204610.KQ)
- Lin Horn Technology Co Ltd (5464.TWO)
- DeviceENG.CO.Ltd (187870.KQ)
- Zomedica Corp. (ZOMDF)
- Anterogen.Co.Ltd (065660.KQ)
- CURATIS N AG (CURN.SW)
- SPSoft Inc. (443670.KQ)
- Shinhung (004080.KS)
- AEWIN Technologies Co.Ltd. (3564.TWO)
- Patria Bank SA (PBK.RO)
- Pharmosa Biopharm Inc. (6875.TWO)
- Chin Hsin Environ Engineering Co., Ltd. (6951.TW)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.